Novo Nordisk A/S (NONOF)
OTCMKTS · Delayed Price · Currency is USD
51.50
+1.24 (2.47%)
Aug 15, 2025, 3:44 PM EDT
Novo Nordisk Revenue
Novo Nordisk had revenue of 76.86B DKK in the quarter ending June 30, 2025, with 12.93% growth. This brings the company's revenue in the last twelve months to 311.94B, up 20.90% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
311.94B DKK
Revenue Growth
+20.90%
P/S Ratio
4.63
Revenue / Employee
4.03M DKK
Employees
77,349
Market Cap
227.24B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 105.45M |
Glass House Brands | 221.55M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.09M |
Silence Therapeutics | 27.17M |
Longduoduo Company | 4.99M |
Novo Nordisk News
- 21 hours ago - Novo Nordisk's Wegovy gets accelerated US FDA approval for liver disease MASH - Reuters
- 22 hours ago - Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH - GlobeNewsWire
- 22 hours ago - Why Novo Nordisk Flew Almost 3% Higher on Friday - The Motley Fool
- 22 hours ago - NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit - PRNewsWire
- 1 day ago - Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst - Benzinga
- 1 day ago - Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst - Benzinga
- 1 day ago - DEADLINE ALERT for FLYW, LMT, SOC, NVO: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - GlobeNewsWire
- 1 day ago - Novo Nordisk Stock Could Benefit From Eli Lilly's Weight-Loss Price Hikes - Barrons